

**From:** [research.listserv@mssm.edu](mailto:research.listserv@mssm.edu)  
**Subject:** [GCO] COVID-19 Funding Opportunities (4/18/21)  
**Date:** Sunday, April 18, 2021 10:45:42 AM

[View in browser](#)

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.

This is a broadcast email sent on behalf of the Sender and/or Department. If you wish to respond, please follow the contact instructions in the message ONLY.

To automatically download images Add Sender to the Safe Senders List.

## Research Services and Resources



Dear Research Community,

Below is a summary of COVID-19 funding opportunities recently released from the funding opportunity database SPIN. Click [here](#) for more information.

Please note that some opportunities have rapidly approaching deadlines. Previous COVID-19 funding opportunities that have been circulated via the listserv are posted on [GCO's Funding Opportunities](#) page and on the [ORS Research Roadmap COVID-19 Funding Opportunities](#) page organized by due date. COVID-19 opportunities funded by the CTSA program of NCATS can also be found in [The Conduit newsletter](#).

In addition, please review the [SPIN Getting Started Instructions](#) for information about beginning your individual search.

The Grants and Contracts Office



Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
1. Research Innovation Collaborations Program	23andme		16-Jul-2021	Not Specified
2. Expanding Disabilities				

Network's (UCEDDs) Access to COVID 19 Vaccines	Administration for Community Living/DHHS		21-Apr-2021	59,701 USD
3. Innovations in Nutrition Programs and Services - Statewide Research	Administration on Aging/DHHS	HHS-2021-ACL-AOA-INNU-0092	28-Apr-2021 [Optional] [LOI/Pre-App]	1,800,000 USD
4. Call for Proposals: Complementary Clinical Trials: Expanding Access to COVID-19 Vaccines and Rapid Response to Clinical Development Gaps	Coalition for Epidemic Preparedness Innovations (CEPI)		28-May-2021	140,000,000 USD
5. CEPI partner NIBSC - Partners for Sourcing Serum or Plasma from Individuals Recovered from Infection with SARS-CoV-2 Variants for the Development of Antibody Working Standards and Reference Panels	Coalition for Epidemic Preparedness Innovations (CEPI)		Continuous Submission	Not Specified
6. Broadening Protection Against SARS-COV-2 and New Broadly Protective Betacoronavirus Candidate Vaccines	Coalition for Epidemic Preparedness Innovations (CEPI)		31-May-2021 [LOI/Pre-App]	Not Specified
7. MTEC - Military-Civilian National Disaster Medical System (NDMS) Interoperability Study (MCNIS) Pilot Implementation Program - Pre-Announcement	Department of the Army	MTEC-21-11-NMDS	30-Apr-2021	Not Specified
8. Ryan White HIV/AIDS Program Part C Early Intervention Services Program: Existing Geographic Service Areas	HIV/AIDS Bureau/HRSA/DHHS	HRSA-22-015	21-Jun-2021	69,000,000 USD
9. Federal Register Weekly Reference Guide - Week of 04-05-21 - 04-09-21	InfoEd Global		Continuous Submission	Not Specified
10. Request for Proposals-- Reducing the Impact of COVID-19 on Farmworker Families	National Center for Farmworker Health		01-May-2021	Not Specified
11. NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)	National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS	PAR-20-084	07-May-2021	400,000 USD
12. RFA-HD-21-033 -- Community Engaged Research on Pregnancy Related and Associated Infections and Sepsis Morbidity and Mortality (UG3/UH3 Clinical Trial Optional)	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-21-033	20-Apr-2021 [Optional] [LOI/Pre-App]	Not Specified
13. RFA-RM-21-021 -- Transformative Research to Address Health Disparities and Advance Health Equity (U01 Clinical Trial Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-RM-21-021	28-Apr-2021 [Optional] [LOI/Pre-App]	Not Specified
14. RFA-RM-21-022 -- Transformative Research to Address Health Disparities and Advance Health Equity at	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-RM-21-022	28-Apr-2021 [Optional] [LOI/Pre-App]	Not Specified

Minority Serving Institutions (U01 Clinical Trial Allowed)				App]
15. RFA-AA-21-002 -- SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trial Not Allowed)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	RFA-AA-21-002	17-Jul-2021 [Optional] [LOI/Pre-App]	750,000 USD
16. RFA-AA-21-004 -- SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R21 Clinical Trial Not Allowed)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	RFA-AA-21-004	17-Jul-2021 [Optional] [LOI/Pre-App]	275,000 USD
17. RFA-AA-21-003 -- SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R03 Clinical Trial Not Allowed)	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	RFA-AA-21-003	17-Jul-2021 [Optional] [LOI/Pre-App]	100,000 USD
18. Notice of Special Interest (NOSI): Deciphering the Mosaic of Glia in the Addicted Brain	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-001	05-Jun-2021	Not Specified
19. Notice of Special Interest (NOSI): Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-041	31-Mar-2022	200,000 USD
20. Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	PAR-20-155	05-Jun-2021	Not Specified
21. Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)	National Institutes of Health/DHHS	NOT-AG-20-022	01-May-2021	Not Specified
22. Research on Bat Immunology (R21 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-184	15-Jul-2021	275,000 USD
23. RFA-MD-21-004 -- Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-MD-21-004	20-Jul-2021 [Optional] [LOI/Pre-App]	2,500,000 USD
24. RFA-AI-21-023 -- Respond: Epidemiology to End the HIV Epidemic (RESPOND: EEE) (R01 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-AI-21-023	30-Jun-2021 [Optional] [LOI/Pre-App]	Not Specified
25. Notice of Special Interest (NOSI): COVID-19 Related School Disruptions Impact on Mental Health, Cognitive, Social, and Emotional Development of Children	National Institutes of Health/DHHS	NOT-MH-21-225	05-Jun-2021	Not Specified
26. Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium (U01 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	PAR-21-213	09-Jun-2021	Not Specified

27. Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health	National Institutes of Health/DHHS	NOT-OD-21-100	07-May-2021	Not Specified
28. Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium Coordinating Center (U24 Clinical Trial Not Allowed)	National Institutes of Health/DHHS	RFA-AG-21-035	09-May-2021 [Optional] [LOI/Pre-App]	Not Specified
29. RFA-CA-21-029 -- Centers on Telehealth Research for Cancer-Related Care (P50 Clinical Trial Required)	National Institutes of Health/DHHS	RFA-CA-21-029	20-Jun-2021 [Optional] [LOI/Pre-App]	4,000,000 USD
30. Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations – RADx-UP Phase II (Emergency Supplement - Clinical Trial Optional)	National Institutes of Health/DHHS	NOT-OD-21-103	24-May-2021	750,000 USD
31. RFA-OD-21-009 -- Emergency Award: RADx-UP - Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trials Optional)	National Institutes of Health/DHHS	RFA-OD-21-009	07-Jul-2021	800,000 USD
32. RFA-OD-21-008 -- Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations – RADx-UP Phase II (U01 Clinical Trial Optional)	National Institutes of Health/DHHS	RFA-OD-21-008	07-Jul-2021	1,500,000 USD
33. CDC COVID-19 Health Policy Fellowship	Oak Ridge Institute for Science and Education	CDC-NCBDDD-2020-0153	31-May-2021	Not Specified
34. CDC Water, Sanitation, and Hygiene Disease (WASH) Fellowship	Oak Ridge Institute for Science and Education	CDC-DFWED-2021-0105	31-May-2021	Not Specified
35. CDC Water, Sanitation, and Hygiene Disease (WASH) Fellowship	Oak Ridge Institute for Science and Education	CDC-DFWED-2021-0105-A	31-May-2021	Not Specified
36. CDC Surveillance and Emergency Response Fellowship	Oak Ridge Institute for Science and Education	<a href="https://www.zintellect.com/Opp...">https://www.zintellect.com/Opp...</a>	30-May-2021	Not Specified
37. CDC COVID and Disabilities Fellowship	Oak Ridge Institute for Science and Education	CDC-NCBDDD-2021-0086-A	28-May-2021	Not Specified
38. Broad PCORI Funding	Patient-Centered Outcomes Research Institute (PCORI)		04-May-2021	3,000,000 USD
39. Expedited Targeted PCORI Funding Announcement: Increasing COVID-19 Vaccine Confidence among LongTerm Care Workers	Patient-Centered Outcomes Research Institute (PCORI)		04-May-2021	5,000,000 USD
40. Innovative Research Award	Rheumatology Research		01-Jun-2021	400,000

	Foundation			USD
41. Distance Learning and Telemedicine Grants	Rural Utilities Service/Department of Agriculture	RUS-21-01-DLT	04-Jun-2021	1,000,000 USD
42. Flicker Fund	Seventh Generation Fund		Continuous Submission	10,000 USD
43. Community Mental Health Centers Grant Program	Substance Abuse & Mental Health Services Administration	SM-21-014	21-May-2021	5,000,000 USD
44. Transit Cooperative Research Program (TCRP) - COVID-19 and Transit Air Quality Protections (Insight Event)	Transportation Research Board	TCRP E-13 [RFP]	03-Jun-2021	120,000 USD
45. Peru New Partnerships and Private Sector Engagement Initiative	U.S. Agency for International Development	72052721APS00001	28-May-2021	Not Specified

**Icahn School of Medicine at Mount Sinai**

1 Gustave L. Levy Place, New York  
NY 10029 United States

PLEASE DO NOT REPLY DIRECTLY TO THIS MESSAGE.  
This is a broadcast email sent on behalf of the Sender and/or  
Department. If you wish to respond, please follow the contact  
instructions in the message ONLY.

## SPIN Funding Opportunities 4/18/21

Links in the Project Title bring the user to more information in InfoEd > SPIN. To access those links first onto [InfoEd](#).

	SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
1.	060608	<a href="#">Research Innovation Collaborations Program</a>	23andme		16-Jul-2021	Not Specified
		Contact Name				
		Contact Telephone				
		Contact Email	<a href="mailto:apply.research@23andme.com">apply.research@23andme.com</a>			
		Sponsor Website	<a href="#">Link to sponsor website</a>			
		Program URL	<a href="#">Link to program URL</a>			
		Deadline Dates (ALL)	16-Jul-2021			
		Synopsis	23andMe endeavors to advance biomedical science through genetic research. The 23andMe Research Innovation Collaborations Program pairs up academic researchers with 23andMe scientists to perform analyses. Through this program, academic researchers can access de-identified, aggregated data from the 23andMe Research Cohort.			
2.	103319	<a href="#">Expanding Disabilities Network's (UCEDDs) Access to COVID 19 Vaccines</a>	Administration for Community Living/DHHS		21-Apr-2021	59,701 USD
		Contact Name	Pam O'Brien, Program Officer			
		Contact Telephone	202-795-7417			
		Contact Email	<a href="mailto:pamela.obrien@acl.hhs.gov">pamela.obrien@acl.hhs.gov</a>			
		Sponsor Website				
		Program URL	<a href="#">Link to program URL</a>			
		Deadline Dates (ALL)	21-Apr-2021			
		Synopsis	The Administration for Community Living (ACL) announced a new funding opportunity to increase vaccine access for people with disabilities. With funding and partnership support			

from the Centers for Disease Control and Prevention (CDC), ACL is providing grants to disability networks to provide critical services to help communities combat COVID-19. A leading priority of this joint effort is to ensure vaccines are equally accessible to the disability population.

3.	103002	<a href="#">Innovations in Nutrition Programs and Services - Statewide Research</a>	Administration on Aging/DHHS	HHS-2021-ACL- AOA-INNU-0092	28-Apr-2021 [Optional][LOI/Pre-App]	1,800,000 USD
		Contact Name	Judy Simon			
		Contact Telephone	202-795-7381			
		Contact Email	<a href="mailto:judy.simon@acl.hhs.gov">judy.simon@acl.hhs.gov</a>			
		Sponsor Website	<a href="#">Link to sponsor website</a>			
		Program URL	<a href="#">Link to program URL</a>			
		Deadline Dates (ALL)	28-Apr-2021 [Optional][LOI/Pre-App], 24-May-2021			
		Synopsis	Through this funding opportunity, the Administration on Aging (AoA), part of the Administration for Community Living (ACL), plans to award approximately 2 cooperative agreements to domestic public or private non-profit entities for a 36 month project period, pending the availability of funding. This funding opportunity provides for competitive grants to be awarded under the Older Americans Act (OAA) Title III authority to develop and implement evidence-based practices for enhancing senior nutrition.			
4.	103527	<a href="#">Call for Proposals: Complementary Clinical Trials: Expanding Access to COVID-19 Vaccines and Rapid Response to Clinical Development Gaps</a>	Coalition for Epidemic Preparedness Innovations (CEPI)		28-May-2021	140,000,000 USD
		Contact Name				
		Contact Telephone				
		Contact Email	<a href="mailto:cfp@cepi.net">cfp@cepi.net</a>			
		Sponsor Website	<a href="#">Link to sponsor website</a>			
		Program URL	<a href="#">Link to program URL</a>			

	Deadline Dates (ALL)	28-May-2021		
	Synopsis	CEPI is pleased to announce a new funding opportunity of up to US \$140 million, contingent upon availability of funds, for clinical trials with the aim to rapidly expand access to and confidence in COVID-19 vaccines by generating clinical evidence in special/sub-populations/age groups or addressing clinical development gaps. Clinical trials which expand access and capacity in low- and middle-income countries (LMICs) are particularly encouraged.		
5.	<a href="#">CEPI partner NIBSC - Partners for Sourcing Serum or Plasma from Individuals Recovered from Infection with SARS-CoV-2 Variants for the Development of Antibody Working Standards and Reference Panels</a>	Coalition for Epidemic Preparedness Innovations (CEPI)	Continuous Submission	Not Specified
103528				
	Contact Name	Giada Mattiuzzo		
	Contact Telephone			
	Contact Email	<a href="mailto:Giada.Mattiuzzo@nibsc.org">Giada.Mattiuzzo@nibsc.org</a>		
	Sponsor Website	<a href="#">Link to sponsor website</a>		
	Program URL	<a href="#">Link to program URL</a>		
	Deadline Dates (ALL)			
	Synopsis	Through a joint effort in 2020, the Coalition for Epidemic Preparedness Innovations (CEPI), the National Institute for Biological Standards and Control (NIBSC), and the World Health Organization (WHO) provided COVID-19 vaccine developers and the entire scientific community with a research reagent for an anti-SARS-CoV-2 antibody, an International Reference Panel and the first WHO International Antibody Standard for assay calibration. These materials are constituted of plasma samples sourced from SARS-CoV-2 convalescent patients.		
6.	<a href="#">Broadening Protection Against SARS-COV-2 and New Broadly Protective Betacoronavirus Candidate Vaccines</a>	Coalition for Epidemic Preparedness Innovations (CEPI)	31-May-2021 [LOI/Pre-App]	Not Specified
103531				



Contact Name	
Contact Telephone	
Contact Email	<a href="mailto:cfp@cepi.net">cfp@cepi.net</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	31-May-2021 [LOI/Pre-App], 01-Oct-2021 [LOI/Pre-App]
Synopsis	CEPI is pleased to announce a new funding opportunity for the development of vaccines with one of the following attributes: broadly protective vaccine against new emerging variants and variants of concern of the SARS-CoV-2 virus (BPCoV2), with funding up to 18-24 months to achieve clinical proof of concept (POC); and a broadly protective Betacoronavirus (BPBC) vaccine with funding potentially awarded for up to 4 years to demonstrate clinical POC. The main focus of this Call for Proposals (CfP) is the research and development of novel immunogens for vaccine constructs able to elicit durable broadly protective responses.

7.	<a href="#">MTEC - Military-Civilian National Disaster Medical System (NDMS) Interoperability Study (MCNIS) Pilot Implementation Program - Pre-Announcement</a>	Department of the Army	MTEC-21-11-NMDS	30-Apr-2021	Not Specified
----	---	------------------------	-----------------	-------------	---------------

Contact Name	Lauren Palestrini
Contact Telephone	718-619-7570
Contact Email	<a href="mailto:lauren.palestrini@mtec-sc.org">lauren.palestrini@mtec-sc.org</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	
Deadline Dates (ALL)	30-Apr-2021
Synopsis	The Medical Technology Enterprise Consortium (MTEC) is excited to post this pre-announcement for an upcoming Other Transaction Agreement (OTA) for prototype project Request for Project Proposals (RPP) that focuses on the development and implementation of the National Disaster Medical System (NDMS) Pilot Program ("Pilot"). The Pilot is a congressionally required prototype, which will serve as a proof of concept to inform

nationwide changes to the existing NDMS. The purpose of the Pilot is to strengthen interoperable partnerships of the NDMS to care for our Nation's combat casualties by increasing medical surge capabilities and capacities at five regional sites. This will be achieved through a collaborative network of federal and civilian NDMS partners. The current Pilot Phase I activities (currently underway during Year 0) will be transitioning (as of September 30, 2021) to Phase II (Pilot Implementation). This upcoming RPP is specifically focused on the activities associated with Phase II, which include conducting further NDMS studies, systematically implementing recommended changes, measuring intervention outcomes, and iteratively making improvements to optimize Pilot performance at the five sites. The information generated in Phase II (which will include those tasks awarded as a result of the upcoming MTEC RPP among other activities outside of this MTEC effort) will inform system-wide changes for nationwide implementation in Phase

III.

---

Background The FY20 National Defense Authorization Act (NDAA) states the Pilot will be conducted over five years at no less than five locations. The FY20 NDAA was reauthorized in FY21 (Section 741), and it directs the Pilot to establish partnerships with public, private, and nonprofit healthcare organizations in these locations. It also directs the Pilot to establish requirements for staffing, specialized training, medical logistics, telemedicine, patient regulating, movement, situational status reporting, tracking, and surveillance. The Pilot will be conducted in collaboration with the Secretaries of Veteran Affairs, Health and Human Services, Homeland Security, and Transportation. These agencies selected the following five (5) sites representing regional NDMS networks at which the Pilot will be conducted: Washington, DC; San Antonio, TX; Sacramento, CA; Omaha, NE; and Denver, CO. The NDMS definitive care partners in these metropolitan regions will be comprised of military and veterans administration healthcare facilities, Federal Coordinating Centers (FCCs), NDMS partner hospitals, and local health departments within a larger metropolitan area. The Pilot will be carried out at these sites over five (5) years in three (3) Phases. Phase I is a study called the Military-Civilian NDMS Interoperability Study (MCNIS) and is already underway. MCNIS is designed to identify the NDMS medical surge issues, gaps, and best practices for each location. MCNIS is being conducted by the Operational Research and Integration Office-National Center for Disaster Medicine and Public Health (ORION). During Phase II, study findings will be incorporated into site specific implementation plans, which will be written and operationalized at each

of the Pilot sites over five (5) years, per the NDAA (See Figure 1 in the attachment included with this announcement). Information, procedures, activities and requirements from each of the sites will be used to develop a model prototype regional system for implementation nationally. Phase III of the Pilot will consist of reporting the results of the Pilot and planning for Pilot expansion in other NDMS locations. Pilot implementation (Phase II), components of which are the focus of this upcoming RPP, will start on September 30, 2021 (although the actual award date for tasks resulting from this upcoming MTEC RPP may differ). During Phase II, ORION will continue to strategically lead and integrate the Pilot effort and continue conducting mixed methods research to assess and guide Pilot operationalization. To complement ORION's research and strategic integration role, a Field Implementation Team (FIT) will be created through this upcoming RPP as the Phase II operational arm of the Pilot. The FIT will execute Pilot implementation through operational lines of effort and Site Operational Coordinators in full coordination with ORION. Of note, this upcoming RPP only applies to tasks assigned to FIT during the first year of the five year Pilot implementation. It does not apply to ORION tasks. The Pilot is functionally and organizationally comprised of ORION and FIT collaboratively working together as one Pilot team to conceive, carry out, and study Pilot implementation at the five sites (See Figure 2 in the attachment included with this announcement). Technical Requirements The intent of this upcoming RPP is to initially award requirements 1-12 in addition to sub-study (A) as described below with a 1-year Period of Performance (PoP). Therefore, all Enhanced White Paper submissions shall propose projects that address requirements 1-12 and sub-study (A). Information regarding sub-studies B-E is provided below in this Pre-Announcement for informational purposes to provide context so the Offeror is aware of work that may be added in a post-award stage, during the initial (12-month) PoP, which may extend the project beyond that initial PoP. Of note, implementation at the five (5) Pilot sites will need to be sustained and studied over the following 48 months (five years total) beyond the initial 12 month PoP [funding for these additional 48 months is unknown at this time]. It is expected that MTEC will make a single award to a qualified team to accomplish all tasks. The NDMS shall be led by a centralized point of contact at the prime performer. It is possible that several subcontractors will be required to accomplish the full scope of the project throughout Phase II (remaining 48 months of Phase II). It is highly recommended that only Offerors interested in the potential to collaborate with others submit proposals in response to this upcoming RPP, as it is possible that the composition of the awarded team may change as the project

requirements evolve over time. The requirements for this prototype project against which Offerors shall propose to execute Phase II (Year one) of the NDMS program are below. Note that Offerors are encouraged to propose the use of commercial off-the-shelf products as much as possible rather than proposing the development of new, unique systems/software to avoid extra cost to the Government related to maintenance and updates in the future. Attend a Phase II Kick-off meeting in September 2021 for a debrief on the Phase I Pilot Study (MCNIS) which is currently ongoing in Year 0 (subject to change depending on the actual award date for this requirement). During this meeting, the MCNIS findings will be presented and validated by the convened Pilot stakeholders. The transition to Phase II, Pilot Implementation, will occur at that time. Provide comprehensive coordination between the ORION staff and each of the five sites, working by/with/through NDMS Pilot partners at each site. Provide five (5) Site Operational Coordinators (SOCs) and support teams/staff to conduct this coordination function. SOCs must have expertise in hospital emergency preparedness and experience in NDMS definitive care roles and responsibilities. Additional support staff are expected to be assigned to complete the below tasks, as directed by the FIT-Integration lead and coordinated with the SOCs at the five sites). Figure 2 illustrates the notional organizational relationships. The Offeror is expected to staff and organize against each requirement appropriately. SOCs and their support teams/staff are expected to be embedded on-site at NCDMPH with ORION staff with frequent calls, meetings, and visits to their respective regions throughout the year. Relocation vs long-distance support/coordination will be assessed for out-years (balance of Phase II time). Additionally, the FIT Integration Lead and requisite support staff are also expected to be on-site embedded with ORION for this PoP. Operational Lines of Effort staff may be on-site, but are not required; the Operational Lines of Effort structure portrayed in Figure 2 is notional and simply intended to convey functional tasks and not staffing level or organization. (Months 1-12) In conjunction with and under the direction of ORION staff and leadership, assess MCNIS Phase I research findings; develop, refine, and translate these findings into Pilot implementation plans for the five pilot sites. (Months 1-6) In conjunction with and under the direction of ORION staff and leadership, establish interoperable Pilot requirements for the following medical surge domains: staffing, specialized training, medical logistics, telemedicine, patient regulating, movement, situational status reporting, tracking, and surveillance. (~Months 1-3) In conjunction with and under the direction of ORION staff and leadership, establish site-agnostic process and outcome metrics to evaluate the effectiveness of the pilot program at all five sites to

include baseline medical surge capacity, capability, and interoperability of the nine medical surge domains. (~Months 1-3) In conjunction with and under the direction of ORION staff and leadership, create medical surge interoperability benchmarks for Pilot sites with associated metrics to measure performance. (~Months 1-3) In conjunction with and under the direction of ORION staff and leadership, work with local federal and civilian NDMS partners at each of the five sites to refine and validate site-specific implementation plans, while also synchronizing core implementation elements across all five sites to ensure consistency, where appropriate. (Months 1-6) In conjunction with and under the direction of ORION staff and leadership, write a master implementation plan and sub-implementation plans for each of the five sites based on MCNIS Phase I findings and site-specific refinement and validation efforts. Implementation plans must establish and strengthen partnerships with “public, private, and nonprofit health care organizations, health care institutions, health care entities, academic medical centers or institutions of higher education and hospitals” to increase the local NDMS interoperability and medical surge capacity to support the definitive care requirements of a large scale overseas conflict. (Months 3-6) In conjunction with and under the direction of ORION staff and leadership, begin to operationalize implementation plans at the five sites in collaboration with NDMS partners (It is expected that implementation will continue beyond this PoP for the remainder of Phase II, pending funding) (Months 6-12) In conjunction with and under the direction of ORION staff and leadership, conduct a federal level Pilot tabletop exercise, to include representation from the five sites, to validate MCNIS findings, refine the master implementation plan, and assess interagency and baseline public/private partnership metrics. (Months 9-12) Provide initial draft Report to Congress to the Sponsor’s Office which will be reviewed and finalized by the Government to inform Congress on the NDMS pilot program in accordance with the NDAA required elements. (Months 1-4) Augment the implementation plans for each Pilot site, based on the direction of ORION staff and leadership and recommendations generated by the Pilot sub-studies (listed below). (Months 6-12) Sub-Study Requirements: (Enhanced White Papers will be required include Sub-study A in the proposed work). However, information below related to Sub-studies B-E is for informational purposes so that Offerors can provide more complete Enhanced White Papers. This work may be added, non-competitively, at any time after the PoP has been initiated [i.e., during the initial 12-month PoP dependent on funding availability and successful completion of milestones]. A. Conduct Sub-study (A): Assess COVID-19 lessons-learned at each Pilot site, specifically translating these lessons-learned into actionable

NDMS recommendations to augment Pilot implementation plan interventions. B. Conduct Sub-study (B): Perform medical surge modeling of national NDMS healthcare capacity, demonstrating the quantity, quality, and duration of available definitive care within the NDMS definitive care hospital partner network over time. Modeling must include three separate cohorts: (1) Military Treatment Facilities, (2) Veterans Affairs Medical Centers, and (3) civilian NDMS definitive care partners. C. Conduct Sub-study (C): Conduct a comprehensive review and analysis of the Federal NDMS legislative landscape, specifically describing: (1) the applicable Federal agency policies, plans, and procedures; and (2) the current Federal laws and regulations governing NDMS and recommending options for new or updated laws and regulations to enable the NDMS to meet the definitive care requirements of a persistent and large scale overseas conflict. Special attention should be given to the gaps/weaknesses in authorities, responsibilities, funding (direct and indirect) and organizational structure of NDMS. D. Conduct Sub-study (D): Conduct a review of the State/Regional NDMS legislative landscape, specifically focused on changes needed to strengthen regional participation in NDMS to support the definitive care requirements of a large-scale overseas conflict. E. Conduct Sub-study (E): Conduct a study of the direct and indirect incentives which may be created, augmented, and/or aligned to ensure non-federal civilian healthcare organizations will support the NDMS definitive care mission when activated. At the end of the 1-year PoP, the following deliverables shall be provided to the Government (or successful completion of milestone(s) shall be demonstrated): Interoperable Pilot requirements for the following medical surge domains: staffing, specialized training, medical logistics, telemedicine, patient regulating, movement, situational status reporting, tracking, and surveillance [deliverable is due no later than January 15, 2022]; Site-agnostic process and outcome metrics to evaluate the effectiveness of the pilot program at all five sites to include baseline medical surge capacity, capability, and interoperability of the nine medical surge domains [deliverable is due no later than January 15, 2022]; Medical surge interoperability benchmarks for Pilot sites with associated metrics to measure performance; A master implementation plan and sub-implementation plans for each of the five sites based on MCNIS phase I findings and site-specific refinement and validation efforts; A federal level Pilot tabletop exercise, to include representation from the five sites, to validate MCNIS findings, refine the master implementation plan, and assess interagency and baseline public/private partnership metrics; Draft report on the NDMS pilot program in accordance with the NDAA required elements for the Sponsor to provide to Congress; Operationalized implementation plans at

the five sites in collaboration with NDMS partners; and Sub-study (A) report which will assess COVID-19 lessons-learned at each Pilot site, specifically translating these lessons-learned into actionable NDMS recommendations to augment Pilot implementation plan interventions. Potential Follow-on Tasks: There is potential for award of one or more follow-on tasks based on the success of any resultant Research Project Awards (subject to change depending upon Government review of work completed). Note that any potential follow on work is expected to be awarded non-competitively to resultant project awardees, potentially as an addition of a new subcontractor(s). Such follow-on work may include (but is not limited to) the following: Continuation of Phase II into Years 2 – 5, potentially with additional sub-studies; Expansion of the program into a Phase III, which will increase the number of sites participating in the Pilot and provide comprehensive recommendations for the entire NDMS. Potential Funding Availability and Period of Performance: The U.S. Government (USG) Department of Defense (DoD) Uniformed Services University of the Health Sciences (USUHS) currently has available a total of approximately \$9.47 million (M) to support technical requirements and sub-studies for Phase II Pilot Implementation. Offerors' EWP shall propose best and final pricing. Therefore, if the total proposed costs for requirements 1-12 and sub-study (A) is estimated to be less than \$9.47 M, then Offerors are invited to propose sub-studies B-E and any additional tasks that would accelerate implementation and/or benefit the effort. If the total proposed work costs more than \$9.47 M, then Offerors are invited to include a ROM that outlines what portion of the work could be accomplished within these funding limits, and how much the remaining tasks would be cost. Cost sharing, including cash and in kind (e.g., personnel or product) contributions are strongly encouraged, have no limit, and are in addition to the Government funding to be provided under the resultant award(s). The USG may apply additional dollars for follow-on efforts via post award modification to any resultant awards after the evaluation and acceptance of work and cost plan. Dependent on the results and deliverables, additional time may be added to the period of performance for follow-on tasks. The anticipated PoP for requirements 1-12 and sub-study A is not to exceed 1 year. However, as the entirety of Phase II (Pilot Implementation) will be conducted over five (5) years, as directed by the NDAA, any resulting award(s) may be modified to extend the PoP and add additional work to further support the overall Phase II activities. Acquisition Approach This upcoming RPP will be conducted using the Enhanced White Paper (EWP) approach. In Stage 1, Offerors are invited to submit proposals in the form of Enhanced White Papers using the mandatory

format (inclusive of a ROM) contained in this upcoming RPP. The Government will evaluate Enhanced White Papers submitted and select the proposal(s) that represents the best value using the evaluation criteria described in the upcoming RPP. The Offeror(s) whose proposed solution is selected for further consideration based on the Enhanced White Paper evaluation will be invited to submit a full cost proposal in Stage 2. This upcoming RPP will be posted to the MTEC website ([mtec-sc.org](http://mtec-sc.org)) and [beta.SAM.gov](http://beta.SAM.gov) to notify interested parties. MTEC membership is required for the submission of an Enhanced White Paper in response to this upcoming MTEC RPP. To join MTEC, please visit <http://mtec-sc.org/how-to-join/> Proposers Conference MTEC will host a Proposers Conference that will be conducted via webinar within two (2) weeks after the release of the RPP. The Proposers Conference is a virtual webinar format that provides potential Offerors the opportunity to interact directly with both MTEC and the Government Sponsor related to this specific funding opportunity. Further information will be provided in the RPP. Additionally, instructions for registration will be forthcoming via email to MTEC members. MTEC Member Teaming While teaming is not required for this effort, Offerors are encouraged to consider teaming during the proposal preparation period (prior to proposal submission) if they cannot address the full scope of technical requirements of the RPP or otherwise believe a team may be beneficial to the Government. MTEC members are encouraged to use the MTEC Database Collaboration Tool to help identify potential teaming partners among other MTEC members. The Database Collaboration Tool provides a quick and easy way to search the membership for specific technology capabilities, collaboration interest, core business areas/focus, R&D highlights/projects, and technical expertise. Contact information for each organization is provided as part of the member profile in the collaboration database tool to foster follow-up conversations between members as needed. The Collaboration Database Tool can be accessed via the "MTEC Profiles Site" tab on the MTEC members-only website. As an alternative to the Collaboration Database Tool, MTEC has also launched a webpage on the MTEC public website specific to this upcoming RPP to help MTEC member organizations team with others in preparation for submission of Enhanced White Papers. Please visit for more details: <https://www.mtec-sc.org/21-11-ndms-desire-to-team-partner/> MTEC The MTEC mission is to assist the U.S. Army Medical Research and Development Command (USAMRDC) by providing cutting-edge technologies and supporting life cycle management to transition medical solutions to industry that protect, treat, and optimize Warfighters' health and performance across the full spectrum of military operations. MTEC is a



biomedical technology consortium collaborating with multiple government agencies under a 10-year renewable Other Transaction Agreement (OTA), Agreement No. W81XWH-15-9-0001, with the U.S. Army Medical Research Acquisition Activity (USAMRAA). MTEC is currently recruiting a broad and diverse membership that includes representatives from large businesses, small businesses, “nontraditional” defense contractors, academic research institutions and not-for-profit organizations.

8.	<a href="#">Ryan White HIV/AIDS Program</a>				
103077	<a href="#">Part C Early Intervention Services Program: Existing Geographic Service Areas</a>	HIV/AIDS Bureau/HRSA/DHHS	HRSA-22-015	21-Jun-2021	69,000,000 USD

Contact Name	Adejumoke Oladele
Contact Telephone	301-443-2441
Contact Email	<a href="mailto:aoladele@hrsa.gov">aoladele@hrsa.gov</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	
Deadline Dates (ALL)	21-Jun-2021
Synopsis	The Health Resources and Services Administration (HRSA) is accepting applications for fiscal year (FY) 2022 – FY 2024 Ryan White HIV/AIDS Program (RWHAP) Part C HIV Early Intervention Services (EIS) Program: Existing Geographic Service Areas. The purpose of this program is to provide comprehensive primary health care and support services in an outpatient setting for low income, uninsured, and underserved people with HIV.

9.	<a href="#">Federal Register Weekly</a>				
103251	<a href="#">Reference Guide - Week of 04-05-21 - 04-09-21</a>	InfoEd Global		Continuous Submission	Not Specified

Contact Name	
Contact Telephone	518-713-4200
Contact Email	<a href="mailto:office@infoedglobal.com">office@infoedglobal.com</a>
Sponsor Website	<a href="#">Link to sponsor website</a>
Program URL	

Deadline Dates (ALL)		Friday, April 9, 2021: ADMINISTRATION FOR COMMUNITY LIVING/DEPARTMENT OF HEALTH AND HUMAN SERVICES announced the availability of funding under the Expanding Disabilities Network's (Protection and Advocacy Systems) Access to COVID-19 Vaccines program (pp. 18538-41). Deadline: 04/23/2021. Contact: Ophelia.mclain@acl.hhs.gov. SPIN Program #: This program is not eligible for SPIN-- eligible applicants are State Protection and Advocacy Agencies. ADMINISTRATION FOR COMMUNITY LIVING/DEPARTMENT OF HEALTH AND HUMAN SERVICES announced the availability of funding under the Expanding Disabilities Network's (Centers for Independent Living) Access to COVID-19 Vaccines program (pp. 18536-38). Deadline: 04/23/2021. Contact: 202-795-7606. SPIN Program #: This program is not eligible for SPIN --eligible applicants are Centers for Independent Living (CILs). OFFICE OF ELEMENTARY AND SECONDARY EDUCATION/DEPARTMENT OF EDUCATION announced a request for comments under the Teacher and School Leader Incentive Program (pp. 18519-23). Deadline for Comments: 05/10/21. Contact: 202-453-6921. SPIN Program #: TBD.			
10.	103476	<a href="#">Request for Proposals--Reducing the Impact of COVID-19 on Farmworker Families</a>	National Center for Farmworker Health	01-May-2021	Not Specified
Contact Name		Paige Menking			
Contact Telephone		512-312-2700			
Contact Email		<a href="mailto:Menking@ncfh.org">Menking@ncfh.org</a>			
Sponsor Website		<a href="#">Link to sponsor website</a>			
Program URL		<a href="#">Link to program URL</a>			
Deadline Dates (ALL)		01-May-2021			
Synopsis		The sponsor is now accepting applications for projects to reduce the impact of COVID-19 on farmworker families. Nonprofit organizations, agricultural employers, and others are encouraged to apply to support programming around COVID-19 vaccination, testing, treatment and prevention. Proposals that focus on harder-to-reach populations, such as communities of indigenous farmworkers, H-2A guest workers, and farmworkers living in congregate housing and/or working in extremely remote rural areas will be prioritized for funding.			

11.	088092	<a href="#">NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)</a>	National Institute of Biomedical Imaging and Bioengineering/NIH/DH HS	PAR-20-084	07-May-2021	400,000 USD
		Contact Name	Randy King, Ph.D.			
		Contact Telephone	301-451-0707			
		Contact Email	<a href="mailto:Randy.King@nih.gov">Randy.King@nih.gov</a>			
		Sponsor Website				
		Program URL	<a href="#">Link to program URL</a>			
		Deadline Dates (ALL)	07-May-2021 , 16-Jun-2021 , 07-Sep-2021 , 16-Oct-2021 , 07-Jan-2022 , 16-Feb-2022 , 07-May-2022 , 16-Jun-2022 , 07-Sep-2022 , 16-Oct-2022 , 07-Jan-2023			
		Synopsis	<p>This Trailblazer Award is an opportunity for NIH-defined New and Early Stage Investigators (<a href="https://grants.nih.gov/policy/early-investigators/index.htm">https://grants.nih.gov/policy/early-investigators/index.htm</a>) to pursue research programs of high interest to the NIBIB that integrate engineering and the physical sciences with the life and/or biomedical sciences. A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven. Importantly, applicants must propose research approaches for which there are minimal or no preliminary data. A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed. Preliminary data are defined as material which the applicant has independently produced and not yet published in a peer-reviewed journal. All preliminary data should be clearly marked and limited to one-half page, which may include one figure. Applications including data more than one-half page or more than one figure will be considered noncompliant with the FOA instructions and will not go forward to review.</p>			
12.	103320	<a href="#">RFA-HD-21-033 -- Community Engaged Research on Pregnancy Related and Associated Infections and Sepsis Morbidity and Mortality (UG3/UH3 Clinical Trial Optional)</a>	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-21-033	20-Apr-2021 [Optional][LOI/Pre-App]	Not Specified

Contact Name	Nahida Chakhtoura MD, MSGH
Contact Telephone	301-435-6872
Contact Email	<a href="mailto:nahida.chakhtoura@mail.nih.gov">nahida.chakhtoura@mail.nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	20-Apr-2021 [Optional][LOI/Pre-App], 20-May-2021
Synopsis	The purpose of this FOA is to support interdisciplinary community-engaged research designed to reduce or eliminate infections and sepsis as causes of pregnancy- related or associated morbidity and mortality (PRAMM) in regions of the United States with high rates of maternal mortality. This FOA is to support research primarily focused on PRAMM health disparities in areas with highest maternal morbidity and mortality. This initiative utilizes the UG3/UH3 Phased Innovation Awards Cooperative Agreement and will be rolled out in 2 phases. Awards for the UG3 phase will be used to demonstrate sufficient preparation, feasibility, and capacity to meet foundational milestones specific to the work proposed. Hypothesis driven objectives will be submitted for the UH3 phase. A UG3 project that meets its milestones will be administratively considered by NICHD and prioritized for transition to the UH3 award. Applicants responding to this FOA must address objectives for both the UG3 and UH3 phases.a

13.	<a href="#">RFA-RM-21-021 -- Transformative Research to Address Health Disparities and Advance Health Equity (U01 Clinical Trial Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-RM-21-021	28-Apr-2021 [Optional][LOI/Pre-App]	Not Specified
-----	---	---	---------------	-------------------------------------	---------------

Contact Name	Stephanie Courchesne-Schlink, Ph.D.
Contact Telephone	301-451-6387
Contact Email	<a href="mailto:CFHealthDisparities@nih.gov">CFHealthDisparities@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	28-Apr-2021 [Optional][LOI/Pre-App], 28-May-2021

		Synopsis	The Transformative Research to Address Health Disparities and Advance Health Equity initiative is soliciting applications to support collaborative investigative teams or individual scientists who propose unusually innovative research projects, which, if successful, would have a major impact in developing, implementing, or disseminating innovative and effective interventions to prevent, reduce, or eliminate health disparities and advance health equity. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in addressing health disparities and inequities.			
14.	103054	<a href="#">RFA-RM-21-022 -- Transformative Research to Address Health Disparities and Advance Health Equity at Minority Serving Institutions (U01 Clinical Trial Allowed)</a>	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-RM-21-022	28-Apr-2021 [Optional][LOI/Pre-App]	Not Specified
		Contact Name	Stephanie Courchesne-Schlink, Ph.D.			
		Contact Telephone	301-451-6387			
		Contact Email	<a href="mailto:CFHealthDisparities@nih.gov">CFHealthDisparities@nih.gov</a>			
		Sponsor Website				
		Program URL	<a href="#">Link to program URL</a>			
		Deadline Dates (ALL)	28-Apr-2021 [Optional][LOI/Pre-App], 28-May-2021			
		Synopsis	The Transformative Research to Address Health Disparities and Advance Health Equity at Minority Serving Institutions initiative is soliciting applications to support collaborative investigative teams or individual scientists who propose unusually innovative research projects, which, if successful, would have a major impact in developing, implementing, or disseminating innovative and effective interventions to prevent, reduce, or eliminate health disparities and advance health equity. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in addressing health disparities and advancing health equity.			
15.	102040	<a href="#">RFA-AA-21-002 -- SARS-CoV-2, COVID-19 and Consequences of</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	RFA-AA-21-002	17-Jul-2021 [Optional][LOI/Pre-App]	750,000 USD

<a href="#">Alcohol Use (R01 Clinical Trial Not Allowed)</a>					
Contact Name		M. Kathy Jung. Ph.D.			
Contact Telephone		301-443-8744			
Contact Email		<a href="mailto:jungma@mail.nih.gov">jungma@mail.nih.gov</a>			
Sponsor Website					
Program URL		<a href="#">Link to program URL</a>			
Deadline Dates (ALL)		17-Jul-2021 [Optional][LOI/Pre-App], 17-Aug-2021			
Synopsis		<p>This Funding Opportunity Announcement (FOA) will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD). Time-sensitive applications for which standard NIH review and funding timelines would compromise either the ability to conduct the research or the value of the knowledge and with the potential to inform responses to the current pandemic will be considered. Applications to this RFA should be accomplished within a three year project duration .</p>			
16.	<a href="#">RFA-AA-21-004 -- SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R21 Clinical Trial Not Allowed)</a>	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	RFA-AA-21-004	17-Jul-2021 [Optional][LOI/Pre-App]	275,000 USD
Contact Name		M. Kathy Jung. Ph.D.			
Contact Telephone		301-443-8744			
Contact Email		<a href="mailto:jungma@mail.nih.gov">jungma@mail.nih.gov</a>			
Sponsor Website					
Program URL		<a href="#">Link to program URL</a>			
Deadline Dates (ALL)		17-Jul-2021 [Optional][LOI/Pre-App], 17-Aug-2021			

Synopsis	<p>This Funding Opportunity Announcement (FOA) will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD). Time-sensitive applications for which standard NIH review and funding timelines would compromise either the ability to conduct the research or the value of the knowledge and with the potential to inform responses to the current pandemic will be considered. This FOA uses the R21 grant mechanism, which is intended to support investigation of novel scientific ideas or new model systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research.</p>
17.  102047	<p> <a href="#">RFA-AA-21-003 -- SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R03 Clinical Trial Not Allowed)</a>  National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS  RFA-AA-21-003  17-Jul-2021 [Optional][LOI/Pre-App]  100,000 USD </p>
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)	<p> M. Kathy Jung. Ph.D.  301-443-8744  <a href="mailto:jungma@mail.nih.gov">jungma@mail.nih.gov</a>    <a href="#">Link to program URL</a>  17-Jul-2021 [Optional][LOI/Pre-App], 17-Aug-2021 </p>
Synopsis	<p>This Funding Opportunity Announcement (FOA) will support research grants to address urgent, time-sensitive research questions on the relationships between alcohol consumption and COVID-19 related outcomes and consequences. The principal area of focus is research that can improve public health in the near term by informing responses to the current COVID-19 pandemic, in view of 1) the impact of alcohol misuse on incidence and severity of COVID-19 disease or 2) the effect of the COVID-19 disease and pandemic-induced restrictions on alcohol use and alcohol use disorder (AUD). Time-sensitive applications for which standard NIH review and funding timelines would compromise</p>

either the ability to conduct the research or the value of the knowledge and with the potential to inform responses to the current pandemic will be considered. This FOA uses the R03 mechanism, which is intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.

18.	103071	<a href="#">Notice of Special Interest (NOSI): Deciphering the Mosaic of Glia in the Addicted Brain</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-001	05-Jun-2021	Not Specified
		Contact Name	Shang-Yi Anne Tsai, Ph.D			
		Contact Telephone	301-827-5842			
		Contact Email	<a href="mailto:stsai@nih.gov">stsai@nih.gov</a>			
		Sponsor Website				
		Program URL	<a href="#">Link to program URL</a>			
		Deadline Dates (ALL)	05-Jun-2021 , 16-Jun-2021 , 25-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 16-Oct-2021 , 25-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 16-Feb-2022 , 25-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 16-Jun-2022 , 25-Jun-2022 , 07-Sep-2022 , 05-Oct-2022 , 16-Oct-2022 , 25-Oct-2022 , 07-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 25-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 16-Jun-2023 , 25-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 25-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 25-Feb-2024 , 07-May-2024 , 05-Jun-2024 , 16-Jun-2024 , 25-Jun-2024 , 07-Sep-2024			
		Synopsis	National Institute on Drug Abuse (NIDA) is issuing this Notice of Special Interest (NOSI) to inform potential applicants of its interest in research project grant submissions that examine the effects of drug use on the structural and functional diversity and plasticity of glia and non-neuronal cells on nervous system process in the context of drug misuse and substance use disorders (SUD). Glial and other non-neuronal cells include astrocytes, microglia, oligodendrocytes and ependymal cells.			
19.	103525	<a href="#">Notice of Special Interest (NOSI): Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus</a>	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-21-041	31-Mar-2022	200,000 USD



	Contact Name	MeLisa Creamer, PhD, MPH				
	Contact Telephone	301-402-1933				
	Contact Email	<a href="mailto:melisa.creamer@nih.gov">melisa.creamer@nih.gov</a>				
	Sponsor Website					
	Program URL	<a href="#">Link to program URL</a>				
	Deadline Dates (ALL)	31-Mar-2022				
	Synopsis	NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for continued research on the impacts of SARS-CoV-2, the coronavirus that causes COVID-19. NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders				
20.	<a href="#">Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	PAR-20-155	05-Jun-2021	Not Specified	
091413						
	Contact Name	Christopher M. Hartshorn, Ph.D.				
	Contact Telephone	240-781-3315				
	Contact Email	<a href="mailto:christopher.hartshorn@nih.gov">christopher.hartshorn@nih.gov</a>				
	Sponsor Website					
	Program URL	<a href="#">Link to program URL</a>				
	Deadline Dates (ALL)	05-Jun-2021 , 05-Oct-2021 , 05-Feb-2022 , 05-Jun-2022				
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, treatment, and/or disease status for cancer or other disease. A distinguishing feature of each application to this FOA will be formation of an academic-industrial partnership: a strategic alliance of academic and industrial investigators who work together as partners to identify and translate a technological solution for mitigation of a cancer (or other disease-related) problem. In this sense, the FOA acts more as funding mechanism for				

driving translational research in imaging more than for a specific scientific or clinical research area. These partnerships are expected to solidify pre-existing collaborations or new ones that would drive the field of imaging, as a whole, further than if they had not been formed. This FOA defines innovation as likelihood to deliver a new capability to end users. This FOA will support clinical trials that test functionality, or validate performance in the chosen setting. This FOA is not intended to support commercial production, basic research projects, or clinical trials that lack translation as the primary motivation.

21.	100302	<a href="#">Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)</a>	National Institutes of Health/DHHS	NOT-AG-20-022	01-May-2021	Not Specified
			Contact Name	Rebecca Fuldner, Ph.D.		
			Contact Telephone	301-402-7748		
			Contact Email	<a href="mailto:fuldnerr@nia.nih.gov">fuldnerr@nia.nih.gov</a>		
			Sponsor Website			
			Program URL	<a href="#">Link to program URL</a>		
			Deadline Dates (ALL)	01-May-2021		
			Synopsis	NIA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19). The mission of NIA is to support and conduct genetic, biological, clinical, behavioral, social, and economic research on aging. This NOSI supports mission critical areas of research for NIA as they relate to the COVID-19 pandemic.		
22.	102912	<a href="#">Research on Bat Immunology (R21 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-184	15-Jul-2021	275,000 USD
			Contact Name	Kentner Singleton, Ph.D.		
			Contact Telephone	240-669-5499		
			Contact Email	<a href="mailto:singletonkl@niaid.nih.gov">singletonkl@niaid.nih.gov</a>		
			Sponsor Website			

	Program URL	<a href="#">Link to program URL</a>				
	Deadline Dates (ALL)	15-Jul-2021 , 15-Mar-2022				
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support research to characterize cellular and molecular constituents of the bat immune system and to understand protective innate and adaptive immune mechanisms in bats.				
23.	102986	<a href="#">RFA-MD-21-004 -- Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-MD-21-004	20-Jul-2021 [Optional][LOI/Pre-App]	2,500,000 USD
	Contact Name	Jennifer Alvidrez, PhD				
	Contact Telephone	301-594-9567				
	Contact Email	<a href="mailto:jennifer.alvidrez@nih.gov">jennifer.alvidrez@nih.gov</a>				
	Sponsor Website					
	Program URL	<a href="#">Link to program URL</a>				
	Deadline Dates (ALL)	20-Jul-2021 [Optional][LOI/Pre-App], 24-Aug-2021				
	Synopsis	This initiative will support (1) observational research to understand the role of structural racism and discrimination (SRD) in causing and sustaining health disparities, and (2) intervention research that addresses SRD in order to improve minority health or reduce health disparities.				
24.	103117	<a href="#">RFA-AI-21-023 -- Respond: Epidemiology to End the HIV Epidemic (RESPOND: EEE) (R01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-AI-21-023	30-Jun-2021 [Optional][LOI/Pre-App]	Not Specified
	Contact Name	Rosemary McKaig, PhD				
	Contact Telephone	240-627-3214				
	Contact Email	<a href="mailto:rmckaig@niaid.nih.gov">rmckaig@niaid.nih.gov</a>				
	Sponsor Website					

	Program URL	<a href="#">Link to program URL</a>				
	Deadline Dates (ALL)	30-Jun-2021 [Optional][LOI/Pre-App], 30-Jul-2021				
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to support applications that address the RESPOND pillar of the Ending the HIV Epidemic: A Plan for America (EHE) initiative. The objective is to better understand HIV susceptibility and ongoing transmission in the United States (U.S.) using local and population-level epidemiology in collaboration with implementing partners. Data generated through this research will inform intervention approaches and facilitate more timely evaluation of context-specific HIV control strategies towards the goal of ending the HIV epidemic in the U.S.				
25.	<a href="#">Notice of Special Interest (NOSI): COVID-19 Related School Disruptions Impact on Mental Health, Cognitive, Social, and Emotional Development of Children</a>	National Institutes of Health/DHHS	NOT-MH-21-225	05-Jun-2021	Not Specified	
103220						
	Contact Name	Susan Borja, PhD				
	Contact Telephone	301-443-1252				
	Contact Email	<a href="mailto:susan.borja@nih.gov">susan.borja@nih.gov</a>				
	Sponsor Website					
	Program URL	<a href="#">Link to program URL</a>				
	Deadline Dates (ALL)	05-Jun-2021 , 07-Sep-2021 , 05-Oct-2021 , 07-Jan-2022 , 05-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 07-Sep-2022				
	Synopsis	NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to understand the mental health impact of the Coronavirus Disease 2019 (COVID-19) pandemic on school-aged children, specifically ages 3 - 12. Particularly, we are interested in the potential impact of primary instruction settings disruptions (e.g., pre-school, elementary school) on the mental health, cognitive, social, and emotional development of children. Empirical data would aid in balancing health risks for various public health mitigation strategies affecting children in the current pandemic as well as inform how to both be prepared and respond to future public health emergencies, including pandemics and disaster scenarios.				

26.

103305	<a href="#">Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium (U01 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	PAR-21-213	09-Jun-2021	Not Specified
	Contact Name	John W.R. Phillips, Ph.D.			
	Contact Telephone	301-496-3136			
	Contact Email	<a href="mailto:John.Phillips@nih.gov">John.Phillips@nih.gov</a>			
	Sponsor Website				
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	09-Jun-2021 , 08-Nov-2021			
	Synopsis	<p>The purpose of this FOA is to advance research on the impact of SARS-CoV-2 and associated mitigation efforts on individual, family, and community behavior and on how subsequent economic disruption affects health-related outcomes, with close attention to underserved and vulnerable populations. To address these questions, this FOA aims to form a research consortium to access, extract, integrate, share, and analyze existing data from various sources with broad population coverage including underserved and vulnerable populations. Examples of existing data include public health data; personal digital data; economic, labor, and commerce data; electronic health records (EHRs); claims data; and ongoing health, demographic, and social surveys. This FOA solicits applications for individual population research projects that will be linked to a Social, Behavioral, and Economic Research on COVID-19 Consortium Coordination Center (SBECCC) to foster collaboration and synergies across consortium member projects. Investigators will work with the SBECCC to enhance as well as share data resources used in proposed research both within the consortium as well as with others for health research purposes. The SBECCC will organize annual meetings of the consortium investigators to share results, foster harmonization among measures collected, identify new opportunities for interaction/collaboration, and share results with NIH and the public. Further, the SBECCC will support the development of reports and analyses summarizing and integrating the findings/products of the consortium.</p>			

27.	103419	<a href="#">Notice of Special Interest (NOSI): Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health</a>	National Institutes of Health/DHHS	NOT-OD-21-100	07-May-2021	Not Specified
		Contact Name	Wendy Nelson, PhD, MPH			
		Contact Telephone	240-276-6971			
		Contact Email	<a href="mailto:nelsonw@mail.nih.gov">nelsonw@mail.nih.gov</a>			
		Sponsor Website				
		Program URL	<a href="#">Link to program URL</a>			
		Deadline Dates (ALL)	07-May-2021 , 05-Jun-2021 , 15-Jun-2021 , 16-Jun-2021 , 10-Aug-2021 , 07-Sep-2021 , 05-Oct-2021 , 15-Oct-2021 , 16-Oct-2021 , 14-Dec-2021 , 07-Jan-2022 , 05-Feb-2022 , 15-Feb-2022 , 16-Feb-2022 , 07-May-2022 , 05-Jun-2022 , 15-Jun-2022 , 16-Jun-2022 , 10-Aug-2022 , 07-Sep-2022 , 05-Oct-2022 , 14-Oct-2022 , 16-Oct-2022 , 14-Dec-2022 , 07-Jan-2023 , 05-Feb-2023 , 15-Feb-2023 , 16-Feb-2023 , 07-May-2023 , 05-Jun-2023 , 15-Jun-2023 , 16-Jun-2023 , 10-Aug-2023 , 07-Sep-2023 , 05-Oct-2023 , 16-Oct-2023 , 17-Oct-2023 , 07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-May-2024 , 05-Jun-2024			
		Synopsis	This Notice of Special Interest (NOSI) is being issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR) with participation from multiple NIH Institutes, Centers, and Offices. This NOSI calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients. Descriptive and intervention research may address adherence determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels. The specific research interests of participating NIH Institutes and Centers are detailed within.			
28.	103421	<a href="#">Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium Coordinating Center (U24 Clinical Trial Not Allowed)</a>	National Institutes of Health/DHHS	RFA-AG-21-035	09-May-2021 [Optional][LOI/Pre- App]	Not Specified
		Contact Name	John W.R. Phillips, Ph.D.			

		Contact Telephone	301-496-3136		
		Contact Email	<a href="mailto:John.Phillips@nih.gov">John.Phillips@nih.gov</a>		
		Sponsor Website			
		Program URL	<a href="#">Link to program URL</a>		
		Deadline Dates (ALL)	09-May-2021 [Optional][LOI/Pre-App], 09-Jun-2021		
		Synopsis	<p>The purpose of this Cooperative Resource-Related Research Project FOA is to establish a coordinating center to support and develop research, dissemination, and various data sharing activities for social, behavioral, and economic research on COVID-19. The Social, Behavioral, and Economic Research on COVID-19 Consortium Coordinating Center (SBECCC) will foster innovation, collaboration, and synergies across researchers funded through the Social, Behavioral and Economic Research on COVID-19 Consortium (U01) program and other relevant NIH-funded studies by supporting networking activities intended to advance research in the field; supporting the development and use of harmonized COVID-19 data constructs for primary and secondary data to support comparability and replicability; assisting in efficient and enhanced sharing/discoverability of data; and disseminating findings to the research community and the public.</p>		
29.	103426	<a href="#">RFA-CA-21-029 -- Centers on Telehealth Research for Cancer-Related Care (P50 Clinical Trial Required)</a>	National Institutes of Health/DHHS	RFA-CA-21-029	20-Jun-2021 [Optional][LOI/Pre-App] 4,000,000 USD
		Contact Name			
		Contact Telephone			
		Contact Email			
		Sponsor Website			
		Program URL	<a href="#">Link to program URL</a>		
		Deadline Dates (ALL)	20-Jun-2021 [Optional][LOI/Pre-App], 20-Jul-2021		
		Synopsis	<p>The purpose of this Funding Opportunity Announcement (FOA) is to fund P50 Centers dedicated to advancing a national telehealth research agenda focused on improving cancer-related care and outcomes across the cancer control continuum in a rapidly changing healthcare, policy, technology, and communication environment. Centers are</p>		

expected to generate and disseminate a robust evidence base for patient-centered, sustainable telehealth models of cancer care delivery. Centers will foster innovations to improve cancer care delivery by researching real-time, patient-provider telehealth communication using new tools, research methods, and technologies. Each Center will focus on one overarching cancer-focused telehealth research theme that will frame the Center's scientific activities. Each Center will leverage a clinical practice network able to support multiple cancer-focused telehealth research studies, including two rapid-cycle pilot projects and one large-scale pragmatic randomized control trial. A centerpiece of each Center, the pragmatic trial will evaluate the integration of telehealth-delivered cancer care into a real-world clinical environment, evaluating improvements in patient access, quality of care, patient-provider communication, and health outcomes. Centers will disseminate evidence-based approaches to telehealth-focused cancer care to the broader clinical care and cancer control communities. Collectively, the P50 Centers on Telehealth Research for Cancer-Related Care will represent a national initiative at the forefront of cancer-related telehealth research committed to improving access to care, care quality, patient-provider communication, and health outcomes across the cancer control continuum.

30.	<a href="#">Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community- engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations – RADx-UP Phase II (Emergency Supplement - Clinical Trial Optional)</a>	National Institutes of Health/DHHS	NOT-OD-21-103	24-May-2021	750,000 USD
-----	---	---------------------------------------	---------------	-------------	----------------

Contact Name	Carol Blaisdell
Contact Telephone	301-435-5606
Contact Email	<a href="mailto:carol.blaisdell@nih.gov">carol.blaisdell@nih.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	24-May-2021



		The National Institutes of Health (NIH) are issuing this NOSI in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This NOSI provides an expedited funding mechanism to support Phase II of the Rapid Acceleration of Diagnostics – Underserved Populations (RADxSM-UP) initiative. These two-year Testing Research Projects will (1) expand the scope and reach of RADxSM-UP testing interventions to reduce COVID-19 disparities among underserved and vulnerable populations and (2) address scientific questions on interventions to increase access and uptake of COVID-19 testing given the increasing availability of SARS-CoV-2 vaccines. The funding for RADxSM-UP is provided from the American Rescue Plan Act of 2021				
31.	103464	<a href="#">RFA-OD-21-009 -- Emergency Award: RADx-UP - Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trials Optional)</a>	National Institutes of Health/DHHS	RFA-OD-21-009	07-Jul-2021	800,000 USD
		Contact Name	Carol Blaisdell			
		Contact Telephone	301-435-5606			
		Contact Email	<a href="mailto:carol.blaisdell@nih.gov">carol.blaisdell@nih.gov</a>			
		Sponsor Website				
		Program URL	<a href="#">Link to program URL</a>			
		Deadline Dates (ALL)	07-Jul-2021			
		Synopsis	High rates and disparities of COVID-19 infection, morbidity, and mortality continue among underserved and vulnerable populations across the United States. The overarching goal of the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative is to understand and ameliorate factors that have placed a disproportionate burden of the pandemic on underserved and/or vulnerable populations, specifically by implementing programs that expand the scope and reach of COVID-19 testing interventions to reduce these disparities. To address barriers to testing and vaccination, social, ethical, and behavioral research is urgently needed to inform related mitigation efforts. This Phase II			

RADx-UP Funding Opportunity Announcement (FOA) is designed to expand research to understand and address the social, ethical, and behavioral implications (SEBI) of COVID-19 testing interventions among underserved and vulnerable populations. Desirable studies for Phase II will move beyond descriptive health disparities research to focus on developing interventions and other actionable solutions in collaboration with community partners and stakeholders. The funding for this initiative is provided from the American Rescue Plan Act of 2021.

32.	103485	<a href="#">RFA-OD-21-008 -- Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations – RADx-UP Phase II (U01 Clinical Trial Optional)</a>	National Institutes of Health/DHHS	RFA-OD-21-008	07-Jul-2021	1,500,000 USD
			Contact Name	Judith A. Arroyo, PhD		
			Contact Telephone	301-402-0717		
			Contact Email	<a href="mailto:jarroyo@mail.nih.gov">jarroyo@mail.nih.gov</a>		
			Sponsor Website			
			Program URL	<a href="#">Link to program URL</a>		
			Deadline Dates (ALL)	07-Jul-2021		
			Synopsis	This funding opportunity announcement (FOA) uses an emergency U01 mechanism to support Phase II of the Rapid Acceleration of Diagnostics – Underserved Populations (RADxSM-UP) initiative. These two-year Testing Research Projects will (1) expand the scope and reach of RADxSM-UP testing interventions to reduce COVID-19 disparities among underserved and vulnerable populations and (2) address scientific questions on interventions to increase access and uptake of COVID-19 testing given the increasing availability of SARS-CoV-2 vaccines. The funding for this initiative is provided from the American Rescue Plan Act of 2021 .		
33.	096765	<a href="#">CDC COVID-19 Health Policy Fellowship</a>	Oak Ridge Institute for Science and Education	CDC-NCBDDD-2020-0153	31-May-2021	Not Specified

		Contact Name				
		Contact Telephone	865-574-7607			
		Contact Email	<a href="mailto:ORISE.CDC.NCBDDD@orau.org">ORISE.CDC.NCBDDD@orau.org</a>			
		Sponsor Website	<a href="#">Link to sponsor website</a>			
		Program URL	<a href="#">Link to program URL</a>			
		Deadline Dates (ALL)	31-May-2021			
		Synopsis	Six research opportunities are currently available in the Division of Birth Defects and Infant Disorders (DBDID), within the National Center on Birth Defects and Developmental Disabilities (NCBDDD) at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia.			
34.	103502	<a href="#">CDC Water, Sanitation, and Hygiene Disease (WASH) Fellowship</a>	Oak Ridge Institute for Science and Education	CDC-DFWED-2021-0105	31-May-2021	Not Specified
		Contact Name				
		Contact Telephone				
		Contact Email	<a href="mailto:CDCrpp@orau.org">CDCrpp@orau.org</a>			
		Sponsor Website	<a href="#">Link to sponsor website</a>			
		Program URL	<a href="#">Link to program URL</a>			
		Deadline Dates (ALL)	31-May-2021			
		Synopsis	A research opportunity is currently available with the Domestic WASH (water, sanitation and hygiene) team, in the Waterborne Disease Prevention Branch, Division of Foodborne, Waterborne, and Environmental Diseases (DFWED), National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia.			
35.	103504	<a href="#">CDC Water, Sanitation, and Hygiene Disease (WASH) Fellowship</a>	Oak Ridge Institute for Science and Education	CDC-DFWED-2021-0105-A	31-May-2021	Not Specified
		Contact Name				
		Contact Telephone				

		Contact Email	<a href="mailto:CDCrpp@orau.org">CDCrpp@orau.org</a>			
		Sponsor Website	<a href="#">Link to sponsor website</a>			
		Program URL	<a href="#">Link to program URL</a>			
		Deadline Dates (ALL)	31-May-2021			
		Synopsis	A research opportunity is currently available with the Domestic WASH (water, sanitation and hygiene) team, in the Waterborne Disease Prevention Branch, Division of Foodborne, Waterborne, and Environmental Diseases (DFWED), National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia.			
36.	103508	<a href="#">CDC Surveillance and Emergency Response Fellowship</a>	Oak Ridge Institute for Science and Education	<a href="https://www.zintelect.com/Oppor-tunity/Details/CD-C-ID-2021-0106">https://www.zintelect.com/Oppor-tunity/Details/CD-C-ID-2021-0106</a>	30-May-2021	Not Specified
		Contact Name				
		Contact Telephone				
		Contact Email	<a href="mailto:ORISE.CDC.NCEZID@orau.org">ORISE.CDC.NCEZID@orau.org</a>			
		Sponsor Website	<a href="#">Link to sponsor website</a>			
		Program URL	<a href="#">Link to program URL</a>			
		Deadline Dates (ALL)	30-May-2021			
		Synopsis	A research opportunity is currently available within the International Reagent Resource (IRR) program, Influenza Division (ID), in the National Center for Immunization and Respiratory Diseases (NCIRD) at the Centers for Disease Control and Prevention (CDC) located in Atlanta, Georgia.			
37.	103514	<a href="#">CDC COVID and Disabilities Fellowship</a>	Oak Ridge Institute for Science and Education	CDC-NCBDDD-2021-0086-A	28-May-2021	Not Specified
		Contact Name				
		Contact Telephone				
		Contact Email	<a href="mailto:ORISE.CDC.NCEZID@orau.org">ORISE.CDC.NCEZID@orau.org</a>			
		Sponsor Website	<a href="#">Link to sponsor website</a>			

	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	28-May-2021			
	Synopsis	Two research training opportunities are currently available as part of the COVID-19 Emergency Operations Center response efforts on the Community Interventions and Critical Populations Task Force/ Disproportionately Affected Populations Team, within the National Center on Birth Defects and Developmental Disabilities (NCBDDD) at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia.			
38.	030477	<a href="#">Broad PCORI Funding</a>	Patient-Centered Outcomes Research Institute (PCORI)	04-May-2021	3,000,000 USD
	Contact Name				
	Contact Telephone	202-827-7700			
	Contact Email	<a href="mailto:info@pcori.org">info@pcori.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	04-May-2021 , 01-Jun-2021 [LOI/Pre-App], 31-Aug-2021			
	Synopsis	The Broad PCORI Funding Announcements (PFAs) seek investigator-initiated applications for patient-centered comparative clinical effectiveness research (CER) projects aligned with our priority areas for research. This PFA covers the following four priority areas outlined in PCORI's National Priorities for Research and Research Agenda: Addressing Disparities; Assessment of Prevention, Diagnosis, and Treatment Options; Communication and Dissemination Research, and Improving Healthcare Systems. These broad areas encompass the patient-centered comparative CER we support.			
39.	103533	<a href="#">Expedited Targeted PCORI Funding Announcement: Increasing COVID-19 Vaccine Confidence among LongTerm Care Workers</a>	Patient-Centered Outcomes Research Institute (PCORI)	04-May-2021	5,000,000 USD
	Contact Name				
	Contact Telephone	202-827-1885			

		Contact Email	<a href="mailto:pfa@pcori.org">pfa@pcori.org</a>		
		Sponsor Website	<a href="#">Link to sponsor website</a>		
		Program URL	<a href="#">Link to program URL</a>		
		Deadline Dates (ALL)	04-May-2021		
		Synopsis	The Patient-Centered Outcomes Research Institute (PCORI) has issued an expedited targeted PCORI Funding Announcement (PFA) to address the following question: What interventions are effective in increasing COVID-19 vaccine confidence and uptake among LongTerm Care (LTC) workers? PCORI has allotted up to \$28 million under this PFA to fund high-quality comparative clinical effectiveness studies that are responsive to the research question of interest.		
40.	095001	<a href="#">Innovative Research Award</a>	Rheumatology Research Foundation	01-Jun-2021	400,000 USD
		Contact Name			
		Contact Telephone	404-365-1373		
		Contact Email	<a href="mailto:foundation@rheumatology.org">foundation@rheumatology.org</a>		
		Sponsor Website	<a href="#">Link to sponsor website</a>		
		Program URL	<a href="#">Link to program URL</a>		
		Deadline Dates (ALL)	01-Jun-2021 , 01-Jul-2021		
		Synopsis	The Innovative Research Award provides independent academic investigators with the funding they need to pursue ideas that could lead to important breakthroughs in discovering new treatments and, one day, a cure. This award provides essential support for innovative studies focused on generating new insights into the cause, progression, treatment, and outcomes of rheumatic and musculoskeletal diseases. The award amount is up to \$400,000 for two years (maximum \$200,000 per year).		
41.	103302	<a href="#">Distance Learning and Telemedicine Grants</a>	Rural Utilities Service/Department of Agriculture	RUS-21-01-DLT 04-Jun-2021	1,000,000 USD
		Contact Name	Randall Millhiser, Acting Deputy Assistant Administrator		
		Contact Telephone	202-720-0800		

	Contact Email	<a href="mailto:dltinfo@usda.gov">dltinfo@usda.gov</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL				
	Deadline Dates (ALL)	04-Jun-2021			
	Synopsis	The Rural Utilities Service (RUS), an agency of the United States Department of Agriculture (USDA), hereinafter referred to as RUS or the Agency, announces its Distance Learning and Telemedicine (DLT) Grant Program application window for Fiscal Year (FY) 2021.			
42.	093072	<a href="#">Flicker Fund</a>	Seventh Generation Fund	Continuous Submission	10,000 USD
	Contact Name				
	Contact Telephone	707-825-7640			
	Contact Email	<a href="mailto:grants@7genfund.org">grants@7genfund.org</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)				
	Synopsis	The Flicker Fund was created as a way to rapidly respond to stressed Indigenous communities on the frontlines of COVID-19. The Fund launched within days of learning about the pervasiveness of the virus and its impact on Indigenous communities.			
43.	103337	<a href="#">Community Mental Health Centers Grant Program</a>	Substance Abuse & Mental Health Services Administration	SM-21-014	21-May-2021
	Contact Name	Asha Stanly			5,000,000 USD
	Contact Telephone	240-276-1845			
	Contact Email	<a href="mailto:asha.stanly@samhsa.hhs.gov">asha.stanly@samhsa.hhs.gov</a>			
	Sponsor Website	<a href="#">Link to sponsor website</a>			
	Program URL	<a href="#">Link to program URL</a>			
	Deadline Dates (ALL)	21-May-2021			

		Synopsis	The Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Mental Health Services (CMHS), is accepting applications for fiscal year (FY) 2021 Community Mental Health Centers grant program. The purpose of this program is to enable community mental health centers to support and restore the delivery of clinical services that were impacted by the COVID-19 pandemic and effectively address the needs of individuals with serious emotional disturbance (SED), serious mental illness (SMI), and individuals with SMI or SED and substance use disorders, referred to as co-occurring disorder (COD). SAMHSA recognizes the needs of individuals with behavioral health conditions, including minority populations and economically disadvantaged communities, have not been met during the pandemic and that CMHC staff and other caregivers have been impacted.			
44.	103413	<a href="#">Transit Cooperative Research Program (TCRP) - COVID-19 and Transit Air Quality Protections (Insight Event)</a>	Transportation Research Board	TCRP E-13 [RFP]	03-Jun-2021	120,000 USD
		Contact Name	Mariela Garcia-Colberg			
		Contact Telephone	202-334-2361			
		Contact Email	<a href="mailto:mgarciacolberg@nas.edu">mgarciacolberg@nas.edu</a>			
		Sponsor Website	<a href="#">Link to sponsor website</a>			
		Program URL	<a href="#">Link to program URL</a>			
		Deadline Dates (ALL)	03-Jun-2021			
		Synopsis	The Transportation Research Board's Transit Cooperative Research Program (TCRP) has issued a request for proposals (RFP) to invite proposals that will assist TCRP in conducting an Insight Event to understand how air quality inside transit vehicles might contribute to the spread of infections. The purpose of this convening event is to allow transit and stakeholders to share their knowledge about the issue of air quality inside vehicles, and help identify possible solutions to the problem and/or areas of research to be undertaken in a future TCRP project.			
45.	103022	<a href="#">Peru New Partnerships and Private Sector Engagement Initiative</a>	U.S. Agency for International Development	72052721APS00001	28-May-2021	Not Specified



Contact Name	G. Michael Junge
Contact Telephone	
Contact Email	<a href="mailto:gjunge@usaid.gov">gjunge@usaid.gov</a>
Sponsor Website	
Program URL	<a href="#">Link to program URL</a>
Deadline Dates (ALL)	28-May-2021 , 02-Jul-2021 , 03-Sep-2021 , 29-Oct-2021 , 28-Jan-2022 , 25-Mar-2022
Synopsis	<p>Peru New Partnerships and Private Sector Engagement Initiative seeks to engage the private and civil sectors in priority areas, as defined by the Government of Peru (GOP) and the United States Government (USG). USAID/Peru will prioritize private and civil sector-driven solutions, multi-stakeholder partnerships for shared value, and innovation.</p> <p>USAID/Peru encourages forging partnerships that promote collaboration with the private sector and civil society in the joint definition of development challenges; identification of the most promising, impactful solutions; and mutual contribution of resources. Focus is placed on local solutions that bring multiple stakeholders to the table to collaborate and systemically change how assistance is transacted, and results are achieved to build a sustainable model that will hopefully continue well into the future. Ideally, solutions will involve building the capacity of the Government of Peru (GOP) so that it will be able to tackle development problems as they arise.</p>